CYB001

CYB001 is a proprietary sublingual formulation of psilocybin being developed by Cybin as a rapidly absorbed psychedelic therapy for major depressive disorder. As a formulation of psilocybin, a serotonergic psychedelic prodrug, CYB001 is converted to psilocin, which acts primarily as an agonist at serotonin 2A receptors in the brain, leading to altered network connectivity and acute psychedelic experiences that are hypothesized to produce durable antidepressant effects. Cybin’s program compares the bioequivalence, pharmacokinetics, and antidepressant efficacy of CYB001 to standard 25 mg oral psilocybin capsules, with the sublingual route intended to bypass first-pass metabolism and accelerate onset while allowing precise dose control in a supervised psychotherapeutic setting.[7][14][15][16]

Other names

psilocybin sublingual formulationsublingual psilocybin formulation